After the mapping of the human DNA by the Human Genome Project, MGRC saw the need to fill what they believed was going to be a huge market in analytics. Even the government has high hopes in this area with a target of 15% contribution to GDP coming from the Bioeconomy. 40 patents and a few loss-bleeding years later, MGRC is beginning to see signs of profitability. The need to achieve greater investor understanding of the field of genetics is probably manifested in its poor share price performance.

See omnystudio.com/listener for privacy information.